Status:
RECRUITING
Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation
Lead Sponsor:
Technische Universität Dresden
Conditions:
Colon Cancer Stage II
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The CIRCULATE study evaluates the adjuvant therapy in patients with colon cancer UICC stage II. The primary aim of the study is to compare the disease free survival in patients who are positive for po...
Detailed Description
CIRCULATE is an investigator-initiated, multicentre, prospective, randomised, controlled trial. Screening phase: Patients with colon cancer (or rectal cancer, if a radiation is not indicated i.e. du...
Eligibility Criteria
Inclusion
- Inclusion criteria for screening phase:
- Resected colon cancer stage II, OR Resected rectal cancer stage II, if there was no indication for radiotherapy (i.e. due to the localisation in the upper third of the rectum ), so that the treatment follows the recommendations for colon cancer. Patients, in whom the tumour stage is not yet know, can be enrolled into the screening.
- Signed informed consent for the screening Phase
- Inclusion criteria for the randomised phase:
- Resected colon cancer stage II, OR resected rectal cancer stage II, if there was no indication for radiotherapy (i.e. due to the localisation in the upper third of the rectum), so that the treatment follows the recommendations for colon cancer.
- Known microsatellite or mismatch repair status
- Confirmation, that the ctDNA result is available
- Signed second informed consent (for the randomised phase)
- Exclusion criteria for Screening:
- Patients with known microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)
- Known clinical high risk situation if it is regarded as certain indication for an adjuvant chemotherapy
- Patients, who have an obvious contra-indication for adjuvant chemotherapy (i.e. due to the performance status, comorbidity, active second cancer or age). It should be considered that patients with an age of more than 75 years frequently not fulfil criteria for adjuvant chemotherapy.
- R1- or R2-status (patients with \[still\] unknown R-status can be screened)
- Patients, in whom the randomisation or chemotherapy is unfeasible due to logistic reasons (travel distance, compliance)
- Age \< 18 years
- Pregnant or breast feeding patients
- Exclusion criteria for randomised phase:
- Patients with microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)
- Known clinical high risk situation if it is regarded as certain indication for an adjuvant chemotherapy
- R1- or R2- status, or unknown R- status (Rx)
- Number of investigated lymph nodes \< 10
- WHO performance status ≥ 2
- Colon or rectal cancer with UICC stage III or IV
- Second cancer, except
- simultaneous or metachronous colon or rectal cancer with UICC stage ≤ I,
- curatively treated basal cell carcinoma or squamous cell carcinoma of the skin and in-situ cervical carcinoma
- tumours with a disease free survival of more than five years
- Contra indications for chemotherapy, especially:
- Leukocytes \< 3,0 Gpt/l
- Neutrophil granulocytes \< 1,5 Gpt/l
- Thrombocytes \< 100 Gpt/l
- alanine aminotransferase (ALAT) or (aspartate aminotransferase) ASAT \> 3x ULN
- Creatinine clearance (calculated according Cockcroft-Gault) \< 30 ml/min
- Comorbidities relevantly interfering with the prognosis of the patients, i.e.:
- heart insufficiency NYHA III/IV
- relevant coronary heart disease,
- Diabetes mellitus with late sequelae
- Organ, stem cell or bone marrow transplantation
- Known hypersensitivity to capecitabine In case of known hypersensitivity to oxaliplatin, the patients can participate, but not receive oxaliplatin
- Medication with brivudine, sorivudine or analogues in the last four weeks before planned treatment start
- Known dihydropyrimidine dehydrogenase (DPD)-deficiency
- Acute infections
- Known HIV- infections, known active hepatitis B or C-infection
- Participation at another interventional study for medical treatment during the last four weeks before randomisation
- Neoadjuvant therapy before resection
- Patients, in whom the randomisation or chemotherapy is unfeasible due to logistic reasons (travel distance, compliance)
- Age \< 18 years
- Pregnant or breast feeding patients
- Women of childbearing potential and men with partner with childbearing potential who are not willing to take appropriate precautions to avoid pregnancy with a highly effective method in case they are randomised to "chemotherapy"
Exclusion
Key Trial Info
Start Date :
June 26 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
4812 Patients enrolled
Trial Details
Trial ID
NCT04089631
Start Date
June 26 2020
End Date
June 1 2026
Last Update
August 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitaetsklinikum Carl Gustav Carus, Medizinische Klinik
Dresden, Saxony, Germany, 01307